Brainstorm Cell Therapeutics Inc.
BCLI- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001137883
No open-market purchases or sales by Brainstorm Cell Therapeutics Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Brainstorm Cell Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Brainstorm Cell Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Frenkel Jacob A | Director | 343,777 | Jul 28, 2026 | 2 |
| Pitts Peter Joe | Executive Chairman | – | Jul 28, 2026 | 1 |
| Arbel Irit | Director | 161,054 | May 29, 2026 | 1 |
| Lebovits Chaim | President & CEO | 2,000,960 | May 29, 2026 | 1 |
| Yablonka Uri | EVP & Chief Business Officer | 218,464 | May 29, 2026 | 1 |
| Patlis Alla | See Remarks | 144,349 | May 29, 2026 | 1 |
| Hartounian Hartoun | Director | 52,000 | May 20, 2026 | 1 |
| Polverino Anthony J. | Director | 25,730 | May 20, 2026 | 1 |
| Lindborg Stacy | Director | 48,229 | May 20, 2026 | 1 |
| Bairu Menghisteab | Director | 24,000 | May 20, 2026 | 1 |
| Naor Nir | Director | 31,465 | May 20, 2026 | 1 |
| Dagher Ibrahim B. | Director | 66,849 | May 20, 2026 | 1 |
| Taylor Kirk | Chief Medical Officer | 35,000 | May 1, 2023 | 0 |
| Kern Ralph Dr. | COO and Chief Medical Officer | 223,310 | Mar 14, 2022 | 0 |
| Taub Malcolm S | Director | 77,332 | Dec 17, 2021 | 0 |
| Almenoff June Sherie | Director | 6,000 | Dec 17, 2021 | 0 |
| Abbhi Sankesh | Director | 11,323 | Dec 10, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2024 (view filing)8:00 AM ET | Sep 30-Oct 1 | 2 days | Lebovits ChaimPresident & CEO | PPurchase | +23.8K | $0.4744 | +$11.3K | +41.7%81.0K after | 2 lots |
| Jul 31, 2024 (view filing)4:07 PM ET | May 10-13 | 82 days | Lebovits ChaimPresident & CEO | PPurchase | +40.0K | $0.4716 | +$18.9K | +3.8%1.10M after | Amended3 lots |
| Jul 31, 2024 (view filing)4:07 PM ET | May 7 | 85 days | Lebovits ChaimPresident & CEO | PPurchase | +66.3K | $0.3743 | +$24.8K | +6.7%1.06M after | Amended |
| Jul 31, 2024 (view filing)4:06 PM ET | May 6 | 86 days | Lebovits ChaimPresident & CEO | PPurchase | +135.0K | $0.3753 | +$50.7K | +15.7%993.6K after | Amended |
| Jul 31, 2024 (view filing) | May 28 | 64 days | Lebovits ChaimPresident & CEO | PPurchase | +15.0K | $0.52 | +$7.80K | +1.3%1.16M after | Amended |
| Jul 31, 2024 (view filing) | May 21-22 | 71 days | Lebovits ChaimPresident & CEO | PPurchase | +50.0K | $0.61 | +$30.5K | +4.5%1.15M after | Amended2 lots |
| Jul 31, 2024 (view filing) | Apr 19 | 103 days | Lebovits ChaimPresident & CEO | PPurchase | +15.0K | $0.52 | +$7.80K | +1.8%858.6K after | Amended |
| Jul 31, 2024 (view filing) | Apr 17-18 | 105 days | Lebovits ChaimPresident & CEO | PPurchase | +245.1K | $0.5406 | +$132.5K | +40.9%843.6K after | Amended2 lots |
| Jul 24, 2024 (view filing)4:05 PM ET | Jul 19 | 5 daysLate | Dagher Ibrahim B.Chief Medical Officer | SSale | −63.0K | $0.3503 | −$22.1K | −100.0%0 after | |
| Sep 5, 2023 (view filing) | Sep 1 | 4 days | Lindborg StacyCo-Chief Executive Officer | PPurchase | +11.5K | $1.77 | +$20.4K | +6.8%181.5K after |